Strong Showing For Novel Bp Lowering Drugs In Resistant Hypertension
The first, dual endothelin receptor antagonist aprocitentan, acts by targeting the endothelin pathway implicated in hypertension. It lowered systolic BP after 4 weeks in the phase III, placebo-controlled PRECISION trial of people with resistant hypertension that did not respond to usual medications, reported Markus Schlaich, MD, of University of Western Australia, Perth. The second drug, baxdrostat, conferred BP reductions over placebo upon 12 weeks of treatment in the BrigHTN study....